BioLineRx Ltd. BLRX
BioLineRx Ltd. (Nasdaq: BLRX) is an oncology drug developer. Its lead program, motixafortide (solid tumors), is in Phase 2 for pancreatic ductal adenocarcinoma (PDAC).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| motixafortide (PDAC, solid tumors outside Asia) | pancreatic cancer | protein/peptide | Phase 2 |
Recent results and decisions
- Oct 23, 2026positive GLIX1 demonstrated synergy with PARP inhibitors in HR-proficient ovarian cancer cell lines and significant tumor growth inhibition in PDX model.
The low-dose combination of GLIX1 (50 mg/kg daily) and olaparib (10 mg/kg daily) demonstrated statistically significant tumor growth inhibition versus vehicle control.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.